Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.

Advertisements

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

Syndromic classification of rickettsioses: an approach for clinical practice Álvaro A. Faccini-Martínez, Lara García-Álvarez, Marylin Hidalgo, José A.

Volume 16, Issue 6, Pages (September 2013)

Prognostic Value of Morning Blood Pressure Surge in Clinical Events: A Meta-analysis of Longitudinal Studies Jun-Chao Xie, Han Yan, Yan-Xin Zhao, PhD,

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

Yun Hyung Koog, Jin Su Lee, Hyungsun Wi

Phase 3 Treatment-Naïve and Treatment-Experienced

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review X.-F. Gao, Z.-W. Yang, J. Li International.

Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother- to-child transmission—a meta-analysis Zhongjie Shi, Xiaomao Li,

Copyright © 2011 American Medical Association. All rights reserved.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Giuseppe Bruno, Annalisa.

Effectiveness of silver-impregnated central venous catheters for preventing catheter- related blood stream infections: a meta-analysis Ya-Mei Chen, Ai-Ping.

Volume 149, Issue 6, Pages (November 2015)

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Yellow fever vaccination status and safety in hemodialysis patients

Systematic review of hepatocellular carcinoma mortality rates among hepatitis B virus- infected renal transplant recipients, with supplemental analyses.

Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis Thomas W. Lee, Michael.

Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Meta-analysis of randomized controlled trials on the efficacy and safety of ondansetron in preventing postanesthesia shivering Min Li, Xiaolan Hu, Yuan.

Amandeep Singh, MD, Harrison J. Alter, MS, MD, Amy Littlepage, MD

Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis Patricia M.

Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Lymph Node Dissection in Clinical Stage I Lung Cancer: A Meta-Analysis and System Review Wenxiong.

The relationship between tumour necrosis factor-α gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in.

Volume 149, Issue 6, Pages (November 2015)

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

Volume 153, Issue 4, Pages (October 2017)

Virological tools to diagnose and monitor hepatitis C virus infection

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 149, Issue 4, Pages e1 (October 2015)

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Y. Wang, X. Chen, Y. Song, B. Caballero, L.J. Cheskin

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Yasuhiko Sugawara, Masatoshi Makuuchi

Volume 155, Issue 5, Pages e2 (November 2018)

Thomas F. O’Donnell, MD, Joseph Lau, MD Journal of Vascular Surgery

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Beating-Heart Versus Conventional On-Pump Coronary Artery Bypass Grafting: A Meta- Analysis of Clinical Outcomes Umar A.R. Chaudhry, MBBS, Leanne Harling,

Volume 130, Issue 4, Pages (April 2006)

New HCV therapies on the horizon

Yousef Rezaei, MD American Journal of Kidney Diseases

Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo-controlled trials E.M. Bartels,

A meta-analysis of dialysis access outcome in elderly patients

Hidde Jongsma, MD, Joost A. Bekken, MD, George P

Biniam Kidane, MD, MSc, Madelaine Plourde, MD, MSc, Sami A

Volume 140, Issue 7, Pages (June 2011)

Factors related to the chronicity and evolution of hepatitis C infection in patients co- infected by the human immunodeficiency virus R. Pérez-Cano, C.

Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials E.M. Bartels, V.N. Folmer, H. Bliddal,

Yin-Shu Chang, MD, Jia-Xiang Wang, MD, PhD, Da-Wei Chang, PhD

Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Troponin elevations after non-cardiac, non-vascular surgery are predictive of major adverse cardiac events and mortality: a systematic review and meta-analysis

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Hepatitis C treatment in patients with kidney disease

This Month in Gastroenterology

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Nicholas Z. Kerin, MD, Sony Jacob, MD The American Journal of Medicine

Gentamicin collagen sponges for the prevention of sternal wound infection: A meta- analysis of randomized controlled trials Michael N. Mavros, MD, Pantelis.

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Reversion of disease manifestations after HCV eradication

Presentation transcript:

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis Tingting Tao, Xuehua Jiang, Yuehong Chen, Yiran Song International Journal of Infectious Diseases Volume 55, Pages 56-71 (February 2017) DOI: 10.1016/j.ijid.2016.12.023 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Flow diagram of study selection. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Forest plot for SVR12 of LDV-SOF versus LDV-SOF+RBV therapy. The central square of each horizontal line represents the RR for each study. The lines demonstrate the range of the 95% CI. The vertical line at an RR of 1 is the line of no effect. % Weight indicates the influence exerted by each study on the pooled RR. LDV=ledipasvir ; SOF=sofosbuvir; CI=confidence interval; M-H=Mantel-Haenszel. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Forest plot of SVR12 based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Forest plot of SVR12 based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Forest plot of SVR12 based on different HCV genotype. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 6 Forest plot of SVR12 based on different hepatic cirrhosis status. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 7 Forest plot for virologic breakthrough and relapse of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 8 Forest plot of virologic failure based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 9 Forest plot of virologic failure based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 10 Forest plot of relapse based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 11 Forest plot of relapse based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 12 Forest plot for the safety outcomes of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 13 Forest plot of discontinuation based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 14 Forest plot of discontinuation based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 15 Forest plot of adverse events based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 16 Forest plot of adverse events based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 17 Forest plot for the adverse events of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 17 Forest plot for the adverse events of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 18 Forest plot of serious adverse events based on different treatment durations. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 19 Forest plot of serious adverse events based on different treatment history. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions

Figure 20 Funnel plot of SVR12. International Journal of Infectious Diseases 2017 55, 56-71DOI: (10.1016/j.ijid.2016.12.023) Copyright © 2017 The Authors Terms and Conditions